MX2021007942A - Metodos y sistemas para proporcionar un regimen de tratamiento personalizado de cannabinoides. - Google Patents
Metodos y sistemas para proporcionar un regimen de tratamiento personalizado de cannabinoides.Info
- Publication number
- MX2021007942A MX2021007942A MX2021007942A MX2021007942A MX2021007942A MX 2021007942 A MX2021007942 A MX 2021007942A MX 2021007942 A MX2021007942 A MX 2021007942A MX 2021007942 A MX2021007942 A MX 2021007942A MX 2021007942 A MX2021007942 A MX 2021007942A
- Authority
- MX
- Mexico
- Prior art keywords
- patient
- systems
- methods
- providing
- values
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
Abstract
Los métodos y sistemas para proporcionar un régimen de tratamiento personalizado con cannabinoides a un paciente incluyen la obtención de genotipos de polimorfismos de nucleótido único (SNP) a partir de una prueba genética del paciente y la modificación de los valores base, como las dosis base o las proporciones básicas, utilizando valores de ponderación que reflejan los genotipos obtenidos para obtener valores de régimen para el tratamiento del paciente. Los valores del régimen tienen en cuenta las respuestas esperadas a los cannabinoides según la información genética del paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862786158P | 2018-12-28 | 2018-12-28 | |
PCT/US2019/068807 WO2020140076A1 (en) | 2018-12-28 | 2019-12-27 | Methods and systems for providing a personalized cannabinoid treatment regimen |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021007942A true MX2021007942A (es) | 2022-06-27 |
Family
ID=71124426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021007942A MX2021007942A (es) | 2018-12-28 | 2019-12-27 | Metodos y sistemas para proporcionar un regimen de tratamiento personalizado de cannabinoides. |
Country Status (6)
Country | Link |
---|---|
US (1) | US20200211688A1 (es) |
EP (1) | EP3902546A4 (es) |
AU (1) | AU2019414963A1 (es) |
CA (1) | CA3125330A1 (es) |
MX (1) | MX2021007942A (es) |
WO (1) | WO2020140076A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11915812B2 (en) | 2019-12-19 | 2024-02-27 | IllumeSense Inc. | System for integrating data for clinical decisions including multiple engines |
US20210193280A1 (en) * | 2019-12-19 | 2021-06-24 | IllumeSense Inc. | System for integrating data for clinical decisions including medicine data and gene data |
US11850064B2 (en) | 2019-12-19 | 2023-12-26 | Markarit ESMAILIAN | System for integrating data for clinical decisions including multiple personal tracking devices |
CA3205403A1 (en) * | 2020-12-14 | 2022-06-23 | Eqalis Group New Zealand Limited | Systems and methods for providing medicine recommendations |
WO2022131933A1 (en) * | 2020-12-14 | 2022-06-23 | Eqalis Group New Zealand Limited | Systems and methods for providing medicine recommendations |
GB2602156A (en) * | 2020-12-21 | 2022-06-22 | Gw Res Ltd | Identification and treatment of patients with epilepsy |
WO2022232933A1 (en) * | 2021-05-04 | 2022-11-10 | Red Light Holland Corp. | Personalized microdosing kits and protocols based on biometric and movement data correlated with natural product qualities |
WO2023135543A1 (en) * | 2022-01-12 | 2023-07-20 | Paolo Poli | Method for evaluating a subject' s response to cannabis treatment |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090087856A1 (en) * | 2007-10-19 | 2009-04-02 | Marshfield Clinic | Method for administering anticoagulation therapy |
EP2485747A4 (en) * | 2008-06-21 | 2013-10-23 | Kenneth Blum | CUSTOMIZATION DIRECTED BY THE DNA OF ANALGESIC COMPOUNDS AS A THERAPEUTIC MODALITY |
US20100304391A1 (en) * | 2009-05-29 | 2010-12-02 | Lombard Jay L | Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis |
US20140274764A1 (en) * | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
WO2015127379A1 (en) * | 2014-02-24 | 2015-08-27 | Children's Hospital Medical Center | Methods and compositions for personalized pain management |
AU2018233582B2 (en) * | 2017-03-16 | 2022-04-07 | CannTab Therapeutics, Limited | Modified release multi-layer tablet cannabinoid formulations |
-
2019
- 2019-12-27 US US16/729,054 patent/US20200211688A1/en active Pending
- 2019-12-27 AU AU2019414963A patent/AU2019414963A1/en active Pending
- 2019-12-27 WO PCT/US2019/068807 patent/WO2020140076A1/en unknown
- 2019-12-27 CA CA3125330A patent/CA3125330A1/en active Pending
- 2019-12-27 MX MX2021007942A patent/MX2021007942A/es unknown
- 2019-12-27 EP EP19905888.4A patent/EP3902546A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3125330A1 (en) | 2020-07-02 |
US20200211688A1 (en) | 2020-07-02 |
AU2019414963A1 (en) | 2021-08-19 |
WO2020140076A1 (en) | 2020-07-02 |
EP3902546A1 (en) | 2021-11-03 |
EP3902546A4 (en) | 2022-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021007942A (es) | Metodos y sistemas para proporcionar un regimen de tratamiento personalizado de cannabinoides. | |
Schmickl et al. | Arabidopsis hybrid speciation processes | |
EP2420835A3 (en) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method | |
NO20050827L (no) | Anvendelse av interferon-B ved behandling av nyresvikt | |
WO2006015087A3 (en) | Thalamic stimulation device | |
TNSN07161A1 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
NO20055832L (no) | Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme | |
BRPI0901509A2 (pt) | métodos e dispositivos para predição de desempenho de um sistema de restrição gástrica | |
WO2003075129A3 (en) | Methods, systems, and software for identifying functional bio-molecules | |
WO2008030273A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
BR112018075894A2 (pt) | método e sistema para ofuscação de dados granulares enquanto retêm privacidade de dados | |
TW200510333A (en) | Benzimidazole compounds | |
BRPI0410634A (pt) | processo | |
ATE446385T1 (de) | Polymorphismen im nod2/card15 gen | |
WO2014165009A3 (en) | Method and apparatus for transmitting healthcare messages to an automatically identified set of patients | |
IL166466A0 (en) | Methods for the treatment of dementia based on apoe genotype | |
WO2008073629A3 (en) | Bifunctional predictors of cancer treatment sensitivity and resistance | |
AU2003302732A1 (en) | Method for identifying risk of breast cancer and treatments thereof | |
GB0310880D0 (en) | Resistance dilution | |
Hoff et al. | Recipient HLA-C haplotypes and microRNA 148a/b binding sites have no impact on allogeneic hematopoietic cell transplantation outcomes | |
NO20073901L (no) | Anvendelse av ostrogen reseptor-B selektive agonister for bestralnings- eller kjemoterapi indusert mucosistis og bestralningscystis | |
Işçi | Genetic relationships of some local and introduced grapes (Vitis vinifera L.) by microsatellite markers | |
MX2021010260A (es) | Interfaz grafica de usuario que muestra el parentesco basado en el adn compartido. | |
NO20021147D0 (no) | Polymorfismer i det humane hPXR-genet og deres anvendelse i diagnostiske og terapeutiske applikasjoner | |
WO2020176461A3 (en) | Methods and compositions for treating neuroendocrine prostate cancer |